Compounded GLP-1 Medications by State: Where They’re Available in 2026

How State Regulation Works

Compounding pharmacy regulation in the United States operates on two levels simultaneously. Federal law (Section 503A and 503B of the FD&C Act) sets the framework, but state pharmacy boards are the primary regulators of 503A pharmacies. This means the rules can differ meaningfully from state to state.

For patients, the critical question isn’t just “Is compounded semaglutide legal?” — it’s “Is the pharmacy I’m considering licensed in my state, and does my state have any additional restrictions?”

When you order from a telehealth provider that ships compounded medication to your home, the compounding pharmacy must hold a valid non-resident pharmacy license in your state (or your state must have a reciprocity arrangement with the pharmacy’s home state). This is one of the most commonly overlooked compliance issues in the industry.

States With Notable GLP-1 Compounding Activity

Texas

Texas hosts the largest concentration of GLP-1 compounding operations in the country. The state’s pharmacy board has been relatively accommodating to compounders, and many of the major telehealth providers use Texas-based 503A pharmacies. However, Texas is also where Judge Mark Pittman ruled on the OFA v. FDA cases, denying injunctions against FDA enforcement. The state’s compounding landscape is active but under increasing federal scrutiny.

Florida

Florida is another major hub for compounding pharmacies, with a large number of 503A facilities serving the state’s significant weight-loss and anti-aging market. The Florida Board of Pharmacy licenses both in-state and out-of-state pharmacies. Florida also has strong telehealth regulations that require providers to establish a legitimate patient-physician relationship before prescribing.

California

California has some of the strictest compounding regulations in the country. The California State Board of Pharmacy has issued specific guidance on GLP-1 compounding and actively monitors compliance. Some compounding pharmacies are not licensed in California, limiting options for patients in the state. If a provider says they “can’t ship to California,” it typically means they haven’t obtained the required California non-resident pharmacy license.

New York

New York requires compounding pharmacies to register with the state Board of Pharmacy and comply with specific compounding regulations. The state has been moderately active in enforcement, particularly regarding out-of-state pharmacies shipping to New York residents without proper licensure.

States With Enhanced Enforcement

Several states have gone beyond the federal baseline with specific enforcement actions against GLP-1 compounding violations:

Connecticut: Attorney General William Tong has been among the most aggressive state enforcers, issuing cease-and-desist letters to medical spas and wellness clinics operating as unlicensed pharmacies and making false “FDA-approved generic” claims.

Ohio: The Ohio State Board of Pharmacy has issued specific guidance on GLP-1 compounding, and the Attorney General has sent warnings to medical spas in the Mahoning Valley for misleading drug marketing.

Illinois: Attorney General Raoul led the 38-state coalition urging stronger FDA action against counterfeit GLP-1 imports, and the state has pursued enforcement against in-state violators.

Kansas: Federal and state authorities pursued significant financial settlements against compounding pharmacies for false claims and improper dispensing.

The Telehealth Factor: Where You Are vs. Where They Are

Most patients access compounded GLP-1 medications through telehealth platforms that pair an online medical consultation with a compounding pharmacy. This creates a multi-state compliance challenge:

The prescribing physician must be licensed in the patient’s state (or the patient’s state must allow telehealth from out-of-state providers under specific conditions).

The compounding pharmacy must be licensed both in its home state and in the patient’s state as a non-resident pharmacy.

The telehealth platform may need separate registrations depending on the state.

When a provider says they “serve 48 states” or “all 50 states,” verify that both their prescribers and their pharmacy are properly licensed in your specific state. The states most commonly excluded from telehealth GLP-1 programs are California (strict pharmacy licensing requirements), certain smaller states where the provider hasn’t obtained licensure, and occasionally states with specific telehealth prescribing restrictions.

How to Verify in Your State

States With Specific GLP-1 Insurance Mandates

A separate but related issue: some states mandate that insurance plans cover GLP-1 medications for weight loss. While this applies to brand-name products (not compounded), it affects the overall access landscape because patients with coverage may not need compounded alternatives. States with GLP-1 coverage mandates for fully-insured plans include North Dakota, Connecticut, Delaware, Maryland, New Jersey, Vermont, and West Virginia.

Important caveat: these mandates only apply to “fully-insured” plans regulated by state law. Large employers that “self-insure” (which covers the majority of large employer plans) are regulated by federal ERISA law and are exempt from state mandates. If you work for a large company, your plan may not be covered by your state’s mandate.